Repligen Corp (RGEN) Q2 2021 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
TFF Pharmaceuticals, Inc. (TFFP) Q1 2021 Earnings Call Transcript Motley Fool Transcribing © The Motley Fool Logo of jester cap with thought bubble.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP)
Q1 2021 Earnings Call
Thank you for standing by. Welcome the TFF Pharmaceuticals Inc. first-quarter 2021 financial and business results conference call. [Operator instructions] As a reminder, today s program may be recorded.Now I like to introduce your host for today s program Paul Sagan, investor relations.
Please go ahead, sir.
Investor Relations
Thank you, operator. Hello, everyone, and welcome to TFF Pharmaceuticals first-quarter 2021 financial and business results conference call. With me on the line today is Glenn Mattes, president and chief executive officer of TFF; Kirk Coleman, chief financial officer; Dr. Dale Christensen, TFF s director of clinical development; Dr.
Christopher Missling
[Audio gap] the quest for disease-confined therapies for neurodegenerative disorders. Separately, the independent Data Monitoring Safety Board, DSMB, also like the ongoing clinical trial program, including the late-stage AVATAR RS-002, EXCELLENCE RS-003, and the US Rett syndrome extension study, RS-EP-001 of Anavex 2-73 has also completed its recent pre-planned review of the respective interim safety data for these three separate clinical studies. Upon review of the interim safety data, the DSMB made the following recommendation for each of the three studies. The DSMB recommendation is to continue the studies without modifications.
This is very good news and indicates we re on the right path with all these studies. As a reminder, our clinical strategy is to clearly differentiate from other biopharma companies and clinical studies in CNS. Anavex is continuing to pioneer the approach of big data, including Anavex in clinical trials to leverage the level of phenot
Good morning, and welcome to the Axsome Therapeutics Conference Call. [Operator Instructions]
I would now like to turn the conference over to your host, Mark Jacobson, Chief Operating Officer at Axsome Therapeutics. Please go ahead.
Mark Jacobson
Chief Operating Officer
Thank you, operator. Good morning, and thank you all for joining us on today s conference call. Our earnings press release providing a corporate update and details of the company s financial results for the first quarter of 2021 crossed the wire a short time ago and is available on our website at axsome.com.
During today s call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our investigational agents, our clinical and non-clinical plans, our plans to present or report additional data, the anticipated conduct in the source of future clinical trials, regulatory plans, future research an
vimarsana © 2020. All Rights Reserved.